Assessment of the cost–effectiveness of a quadrivalent HPV vaccine in Norway using a dynamic transmission model

References

• Walboomers J, Jacobs M, Manos M et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol.189(1), 12–19 (1999).
   PubMed Web of Science ®Google Scholar
• Baseman J, Koutsky L. The epidemiology of human papillomavirus infections. J. Clin. Virol.32(Suppl. 1), S16–S24 (2005).
   PubMed Web of Science ®Google Scholar
• Jacobs M, de Roda Husman A, van den Brule A, Snijders P, Meijer C, Walboomers J. Group-specific differentiation between high- and low-risk human papillomavirus genotypes by general primer-mediated PCR and two cocktails of oligonucleotide probes. J. Clin. Microbiol.33(4), 901–905 (1995).
   PubMed Web of Science ®Google Scholar
• Smith JS, Lindsay L, Hoots B et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int. J. Cancer121(3), 621–632 (2007).
   PubMed Web of Science ®Google Scholar
• Clifford G, Gallus S, Herrero R et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet366(9490), 991–998 (2005).
   PubMed Web of Science ®Google Scholar
• von Krogh G. Management of anogenital warts (condylomata acuminata). Eur. J. Dermatol.11(6), 598–603 (2001).
   PubMed Web of Science ®Google Scholar
• Maw R, Reitano M, Roy M. An international survey of patients with genital warts: perceptions regarding treatment and impact on lifestyle. STD AIDS9, 571–578 (1998).
   PubMed Web of Science ®Google Scholar
• Lacey C, Lowndes C, Shah K. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine24(S3), 35–41 (2006).
   Web of Science ®Google Scholar
• Munoz N, Castellsague X, Berrington de Gonzalez A, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine24(Suppl. 3), S1–S10 (2006).
   Web of Science ®Google Scholar
• Nygard J, Skare G, Thoresen S. The cervical cancer screening programme in Norway, 1992–2000: changes in Pap smear coverage and incidence of cervical cancer. J. Med. Screen.9(2), 86–91 (2002).
   PubMed Web of Science ®Google Scholar
• Cancer Registry of Norway. Cancer in Norway 2006 – Cancer incidence, mortality, survival and prevalence in Norway. Oslo. (2007).
   Google Scholar
• Norwegian Institute of Public Health. Evaluation and recommendation for the use of the HPV vaccine. (2007).
   Google Scholar
• Joura E, Leodolter S, Hernandez-Avila M et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet,1693–1702 (2007).
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMEA). Gardasil European Public Assessment Report (EPAR). 1–40 (2008).
   Google Scholar
• Dasbach E, Elbasha E, Insinga R. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol. Rev.28(1), 88–100 (2006).
   PubMed Web of Science ®Google Scholar
• Bergeron C, Largeron N, McAllister R, Mathevet P, Remy V. Cost–effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France. Int. J. Technol. Assess. Health Care24, 10–19 (2008).
   PubMed Web of Science ®Google Scholar
• Barnabas R, Laukkanen P, Koskela P, Kontula O, Lehtinen M, Garnett G. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med.3(5), e138 (2006).
   PubMed Web of Science ®Google Scholar
• Kim J, Andres-Beck B, Goldie S. The value of including boys in an HPV vaccination programme: a cost–effectiveness analysis in a low-resource setting. Br. J. Cancer97, 1322–1328 (2007).
   PubMed Web of Science ®Google Scholar
• Goldhaber-Fiebert J, Stout NK, Salomon JA, Kuntz KM, Goldie SJ. Cost–effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J. Natl Cancer Inst.100(5), 308–320 (2008).
   PubMed Web of Science ®Google Scholar
• Kulasingam S, Connelly L, Conway E. A cost–effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. Sex. Health,165–175 (2007).
   PubMed Web of Science ®Google Scholar
• Kulasingam SL, Benard S, Barnabas R, Largeron N, Myers ER. Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: a cost–effectiveness analysis. Cost Eff. Resour. Alloc.6, 4 (2008).
   PubMedGoogle Scholar
• Brisson M, Van de Velde N, De Wals P, Boily MC. The potential cost–effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine25(29, 5399–5408 (2007).
   PubMed Web of Science ®Google Scholar
• Elbasha E, Dasbach E, Insinga R. Model for assessing human papillomavirus vaccination strategies. Emerg. Infect. Dis.13(1), 28–41 (2007).
   PubMed Web of Science ®Google Scholar
• French K, Barnabas R, Lehtinen M et al. Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland. Br. J. Cancer96(3), 514–518 (2007).
   PubMed Web of Science ®Google Scholar
• Regan D, Philp D, Hocking J, Law M. Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia. Sex. Health4(3), 147–163 (2007).
   PubMed Web of Science ®Google Scholar
• Günther O, Ogilvie G, Naus M et al. Protecting the next generation: what is the role of the duration of human papillomavirus vaccine-related immunity? J. Infect. Dis.197(12), 1653–1661 (2008).
   PubMed Web of Science ®Google Scholar
• Kim J, Goldie S. Health and economic implications of HPV vaccination in the United States. N. Engl. J. Med.359(8), 821–832 (2008).
   PubMed Web of Science ®Google Scholar
• Neilson A. Freislebel de Blasio. Økonomisk evaluering av humant papillomavirus (HPV)-vaksinasjon i Norge. Rapport Nr 12–2007. Oslo. Nasjonalt kunnkapssenter for hesetjenesten, (2007).
   Google Scholar
• Dasbach E, Insinga R, Elbasha E. The epidemiologic and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the United Kingdom. BJOG (2008).
   PubMed Web of Science ®Google Scholar
• Insinga R, Dasbach E, Elbasha E, Puig A, Reynales-Shigematsu L. Cost–effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation. Vaccine26(1), 128–139 (2007).
   PubMed Web of Science ®Google Scholar
• Bjorge T, Gunbjorud A, Haugen O, Skare G, Trope C, Thoresen S. Mass screening for cervical cancer in Norway: evaluation of the pilot project. Cancer Causes Control6(6), 477–484 (1995).
   PubMed Web of Science ®Google Scholar
• Chesson H, Ekwueme D, Saraiya M, Markowitz L. Cost–effectiveness of human papillomavirus vaccination in the United States. Emerg. Infect. Dis.14(2), 244–251 (2008).
   PubMed Web of Science ®Google Scholar
• The Directorate for Health and Social Affairs. Activity Based Financing. (2003).
   Google Scholar
• The Norwegian Medical Association. Fee schedule for private practicing specialists. (2003).
   Google Scholar
• Ministry of Health and Care. Fee schedule for outpatient care. (2003).
   Google Scholar
• Insinga R, Dasbach E, Myers E. The health and economic burden of genital warts in a set of private health plans in the United States. Clin. Infect. Dis.36(11), 1397–1403 (2003).
   PubMed Web of Science ®Google Scholar
• Norwegian Institute of Public Health. National Survey of Sexuality and Health. (2002).
   Google Scholar
• National Institute for Clinical Excellence. Guide to the Methods of Technology Appraisals. (2004).
   Google Scholar
• The Norwegian Medicines Control Authority. Norwegian guidelines for pharmacoeconomic analysis in connection with applications for reimbursement. (2000).
   Google Scholar
• Evans C. Use of Quality adjusted life years and life year gained as benchmarks in economic evaluations: a critical appraisal. Health Care Manag. Sci.7, 43–49 (2004).
   PubMedGoogle Scholar
• Norwegian Directorate of Health. Sosial- og helsedirektoratet. Helseeffekter i samfunnsøkonomiske analyser. Order-number IS-1435. (2007).
   Google Scholar
• Barnabas R, Kulasingam S. Economic evaluations of human papillomavirus vaccines. Expert Rev. Pharmacoeconomics Outcomes Res.7(3), 251–267 (2007).
   PubMedGoogle Scholar
• Edmunds W, Medley G, Nokes D. Evaluating the cost–effectiveness of vaccination programmes: a dynamic perspective. Stat. Med.18, 3263–3282 (1999).
   PubMed Web of Science ®Google Scholar
• Villa L. Quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle vaccine: first analysis of cross-protection against cervical intraepithelial neoplasia (CIN) and adenocarcinoma in situ (AIS) caused by oncogenic HPV types in addition to 16/18. EUROGIN, 1–1 (2007).
   Google Scholar
• Carter J, Madeleine M, Shera K et al. Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites. Cancer Res.61(5), 1934–1940 (2001).
   PubMed Web of Science ®Google Scholar
• Hobbs C, Sterne J, Bailey M, Heyderman R, Birchall M, Thomas S. Human papillomavirus and head and neck cancer: a systematic review and meta-analysis. Clin. Otolaryngol.31(4), 259–266 (2006).
   PubMed Web of Science ®Google Scholar
• Freed G, Derkay C. Prevention of recurrent respiratory papillomatosis: role of HPV vaccination. Int. J. Pediatr. Otorhinolaryngol.70(10), 1799–1803 (2006).
   PubMed Web of Science ®Google Scholar
• Barr E, Tamms G. Quadrivalent human papillomavirus vaccine. Clin. Infect. Dis.45, 609–617 (2008).
   Web of Science ®Google Scholar